Integrum implements new compensation package for its CEO
Mölndal, Sweden, March 28 2025 — Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has implemented a new compensation package for its Board Director and Acting CEO Scott Flora.
“Integrum is currently undergoing a major strategic shift. As part of this work, the board has renegotiated Acting CEO Scott Flora’s compensation package to increase focus on performance-based compensation. The recruitment of a permanent CEO is ongoing, and the new agreement with Scott Flora provides continued stability and growth focus in the executive management team during this transition phase,” comments Kristofer Westergren, Board Director of Integrum and coordinator of the business assessment and strategic shift.
The new incentive program is based on Stock Appreciation Rights ("SARs") for the Board Member and Acting CEO Scott Flora. Within the framework of the program, Scott Flora has been granted 200,000 SARs, where each vested SAR entitles to a compensation based on Integrum’s share price, but not exceeding SEK 60, on the day of exercise of the vested SARs, less an exercise price (so-called Base Price) amounting to SEK 29.30 per SAR. The granted SARs will vest at a rate of 20 percent every three months starting from June 1, 2025. Unvested SARs will lapse and will not entitle the holder to any payment. A vested SAR shall be exercisable during 1 September 2026 to 31 October 2026. The SAR payment may be paid in stock or in cash, at the Integrums election.
In connection with the new incentive program taking effect, the fixed compensation to Scott Flora will be reduced. The incentive program falls within the framework of the guidelines for compensation to senior executives adopted at Integrum's most recent shareholders' meeting.
For more information, please contact:
Jörgen Svanström, CFO
Phone: + 46 (0) 70 734 96 60
E-mail: Jorgen.svanstrom@integrum.se
Certified Adviser
Carnegie Investment Bank AB (publ) is the company’s Certified Adviser.
About integrum
Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/.